A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia

Mark F. Lew, Allison Brashear, Khashayar Dashtipour, Stuart Isaacson, Robert A. Hauser, Pascal Maisonobe, Daniel Snyder, William Ondo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose/aim: AbobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is an acetylcholine release inhibitor and a neuromuscular blocking agent. The United States prescribing information for abobotulinumtoxinA previously indicated only one dilution for cervical dystonia: 500 U/1 mL. Clinical trial data supporting a larger volume with a 500 U/2 mL dilution would offer clinicians flexibility with injection volume to better meet patient needs. Materials and methods: We conducted a 12-week, phase 3b, multicenter, randomized, double-blind, placebo-controlled trial (NCT01753310). Adult subjects with a primary diagnosis of cervical dystonia were randomized (2:1) to receive a single injection of either abobotulinumtoxinA, 500 U/2 mL dilution, or placebo. The primary efficacy endpoint was changed from baseline in Toronto Western Spasmodic Torticollis Rating Scale total score at Week 4. Results: A total of 134 subjects (abobotulinumtoxinA, n = 89; placebo, n = 45) were randomized (intent-to-treat population) and 129 (abobotulinumtoxinA, n = 84; placebo, n = 45) completed the Week 4 primary endpoint evaluation (modified intent-to-treat population). In the modified intent-to-treat population, subjects receiving abobotulinumtoxinA experienced significantly greater changes from baseline versus placebo on the primary endpoint (weighted overall treatment difference −8.3, P < 0.001). The most common treatment-emergent adverse events (TEAEs) were dysphagia, muscle weakness, neck pain and headache. Overall, TEAEs were consistent with those reported in the abobotulinumtoxinA prescribing information (1 mL dilution) for cervical dystonia patients. Conclusions: This trial provides evidence that a 500 U/2 mL dilution is an effective treatment for cervical dystonia and exhibits a safety profile consistent with the known safety profile of abobotulinumtoxinA.

Original languageEnglish (US)
Pages (from-to)619-626
Number of pages8
JournalInternational Journal of Neuroscience
Volume128
Issue number7
DOIs
StatePublished - Jul 3 2018
Externally publishedYes

Fingerprint

Torticollis
Placebos
Population
Neuromuscular Blocking Agents
Safety
abobotulinumtoxinA
Injections
Neck Pain
Muscle Weakness
Therapeutics
Deglutition Disorders
Headache
Clinical Trials

Keywords

  • AbobotulinumtoxinA
  • cervical dystonia
  • onabotulinumtoxinA
  • spasmodic torticollis
  • TWSTRS

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo : randomized study in cervical dystonia. / Lew, Mark F.; Brashear, Allison; Dashtipour, Khashayar; Isaacson, Stuart; Hauser, Robert A.; Maisonobe, Pascal; Snyder, Daniel; Ondo, William.

In: International Journal of Neuroscience, Vol. 128, No. 7, 03.07.2018, p. 619-626.

Research output: Contribution to journalArticle

Lew, Mark F. ; Brashear, Allison ; Dashtipour, Khashayar ; Isaacson, Stuart ; Hauser, Robert A. ; Maisonobe, Pascal ; Snyder, Daniel ; Ondo, William. / A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo : randomized study in cervical dystonia. In: International Journal of Neuroscience. 2018 ; Vol. 128, No. 7. pp. 619-626.
@article{ab8c05452649464a873437f1359c47bf,
title = "A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia",
abstract = "Purpose/aim: AbobotulinumtoxinA (Dysport{\circledR}, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is an acetylcholine release inhibitor and a neuromuscular blocking agent. The United States prescribing information for abobotulinumtoxinA previously indicated only one dilution for cervical dystonia: 500 U/1 mL. Clinical trial data supporting a larger volume with a 500 U/2 mL dilution would offer clinicians flexibility with injection volume to better meet patient needs. Materials and methods: We conducted a 12-week, phase 3b, multicenter, randomized, double-blind, placebo-controlled trial (NCT01753310). Adult subjects with a primary diagnosis of cervical dystonia were randomized (2:1) to receive a single injection of either abobotulinumtoxinA, 500 U/2 mL dilution, or placebo. The primary efficacy endpoint was changed from baseline in Toronto Western Spasmodic Torticollis Rating Scale total score at Week 4. Results: A total of 134 subjects (abobotulinumtoxinA, n = 89; placebo, n = 45) were randomized (intent-to-treat population) and 129 (abobotulinumtoxinA, n = 84; placebo, n = 45) completed the Week 4 primary endpoint evaluation (modified intent-to-treat population). In the modified intent-to-treat population, subjects receiving abobotulinumtoxinA experienced significantly greater changes from baseline versus placebo on the primary endpoint (weighted overall treatment difference −8.3, P < 0.001). The most common treatment-emergent adverse events (TEAEs) were dysphagia, muscle weakness, neck pain and headache. Overall, TEAEs were consistent with those reported in the abobotulinumtoxinA prescribing information (1 mL dilution) for cervical dystonia patients. Conclusions: This trial provides evidence that a 500 U/2 mL dilution is an effective treatment for cervical dystonia and exhibits a safety profile consistent with the known safety profile of abobotulinumtoxinA.",
keywords = "AbobotulinumtoxinA, cervical dystonia, onabotulinumtoxinA, spasmodic torticollis, TWSTRS",
author = "Lew, {Mark F.} and Allison Brashear and Khashayar Dashtipour and Stuart Isaacson and Hauser, {Robert A.} and Pascal Maisonobe and Daniel Snyder and William Ondo",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/00207454.2017.1406935",
language = "English (US)",
volume = "128",
pages = "619--626",
journal = "International Journal of Neuroscience",
issn = "0020-7454",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo

T2 - randomized study in cervical dystonia

AU - Lew, Mark F.

AU - Brashear, Allison

AU - Dashtipour, Khashayar

AU - Isaacson, Stuart

AU - Hauser, Robert A.

AU - Maisonobe, Pascal

AU - Snyder, Daniel

AU - Ondo, William

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Purpose/aim: AbobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is an acetylcholine release inhibitor and a neuromuscular blocking agent. The United States prescribing information for abobotulinumtoxinA previously indicated only one dilution for cervical dystonia: 500 U/1 mL. Clinical trial data supporting a larger volume with a 500 U/2 mL dilution would offer clinicians flexibility with injection volume to better meet patient needs. Materials and methods: We conducted a 12-week, phase 3b, multicenter, randomized, double-blind, placebo-controlled trial (NCT01753310). Adult subjects with a primary diagnosis of cervical dystonia were randomized (2:1) to receive a single injection of either abobotulinumtoxinA, 500 U/2 mL dilution, or placebo. The primary efficacy endpoint was changed from baseline in Toronto Western Spasmodic Torticollis Rating Scale total score at Week 4. Results: A total of 134 subjects (abobotulinumtoxinA, n = 89; placebo, n = 45) were randomized (intent-to-treat population) and 129 (abobotulinumtoxinA, n = 84; placebo, n = 45) completed the Week 4 primary endpoint evaluation (modified intent-to-treat population). In the modified intent-to-treat population, subjects receiving abobotulinumtoxinA experienced significantly greater changes from baseline versus placebo on the primary endpoint (weighted overall treatment difference −8.3, P < 0.001). The most common treatment-emergent adverse events (TEAEs) were dysphagia, muscle weakness, neck pain and headache. Overall, TEAEs were consistent with those reported in the abobotulinumtoxinA prescribing information (1 mL dilution) for cervical dystonia patients. Conclusions: This trial provides evidence that a 500 U/2 mL dilution is an effective treatment for cervical dystonia and exhibits a safety profile consistent with the known safety profile of abobotulinumtoxinA.

AB - Purpose/aim: AbobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is an acetylcholine release inhibitor and a neuromuscular blocking agent. The United States prescribing information for abobotulinumtoxinA previously indicated only one dilution for cervical dystonia: 500 U/1 mL. Clinical trial data supporting a larger volume with a 500 U/2 mL dilution would offer clinicians flexibility with injection volume to better meet patient needs. Materials and methods: We conducted a 12-week, phase 3b, multicenter, randomized, double-blind, placebo-controlled trial (NCT01753310). Adult subjects with a primary diagnosis of cervical dystonia were randomized (2:1) to receive a single injection of either abobotulinumtoxinA, 500 U/2 mL dilution, or placebo. The primary efficacy endpoint was changed from baseline in Toronto Western Spasmodic Torticollis Rating Scale total score at Week 4. Results: A total of 134 subjects (abobotulinumtoxinA, n = 89; placebo, n = 45) were randomized (intent-to-treat population) and 129 (abobotulinumtoxinA, n = 84; placebo, n = 45) completed the Week 4 primary endpoint evaluation (modified intent-to-treat population). In the modified intent-to-treat population, subjects receiving abobotulinumtoxinA experienced significantly greater changes from baseline versus placebo on the primary endpoint (weighted overall treatment difference −8.3, P < 0.001). The most common treatment-emergent adverse events (TEAEs) were dysphagia, muscle weakness, neck pain and headache. Overall, TEAEs were consistent with those reported in the abobotulinumtoxinA prescribing information (1 mL dilution) for cervical dystonia patients. Conclusions: This trial provides evidence that a 500 U/2 mL dilution is an effective treatment for cervical dystonia and exhibits a safety profile consistent with the known safety profile of abobotulinumtoxinA.

KW - AbobotulinumtoxinA

KW - cervical dystonia

KW - onabotulinumtoxinA

KW - spasmodic torticollis

KW - TWSTRS

UR - http://www.scopus.com/inward/record.url?scp=85041119101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041119101&partnerID=8YFLogxK

U2 - 10.1080/00207454.2017.1406935

DO - 10.1080/00207454.2017.1406935

M3 - Article

C2 - 29343142

AN - SCOPUS:85041119101

VL - 128

SP - 619

EP - 626

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

SN - 0020-7454

IS - 7

ER -